

Creating Global Solutions



19 to 22 October 2010
Melbourne Convention and Exhibition Centre
www.ausbiotech2010.com.au



AUSBIOTECH 2010 PROGRAM*

TUESDAY 19 OCTOBER

| | |
|-----------------|--|
| 8:00am – 7:00pm | Delegate Registration Desk Open <i>Concourse Melbourne Exhibition Centre (Clarendon St End)</i> |
| 9:30am – 4:00pm | AUSBIOTECH AUSTRALASIAN LIFE SCIENCES INVESTMENT SUMMIT <i>By Invitation Only</i> <i>AusBiotech Australasian Life Sciences Summit - Hilton on the Park, East Melbourne</i> <i>Sponsored by Australian Securities Exchange, Australian Trade Commission, Blueprint Life Science Group, RBS Morgan and the Victorian State Government</i> |
| 9:00am – 5:00pm | SATELLITE EVENTS 9:00am – 4:30pm BioBasics in one day - industry knowledge for the non-scientist Level 2, Melbourne Exhibition Centre, 2 Clarendon Street, Melbourne Separate registration required, further information at www.ausbiotech2010.com.au 9:00am – 4:30pm MBA in a Day – business basics for the bioscientist course Level 2, Melbourne Exhibition Centre, 2 Clarendon Street, Melbourne Separate registration required, further information at www.ausbiotech2010.com.au 9:00am – 4:30pm Smart IP Management – Putting the IP Manual into Practice Level 2, Melbourne Exhibition Centre, 2 Clarendon Street, Melbourne Separate registration required, further information at www.ausbiotech2010.com.au |

| | |
|-----------------|--|
| 2:00pm – 5:00pm | BIOINDUSTRY EXHIBITION HALL OPEN TO ALL DELEGATES |
| 3:30pm – 4:00pm | Afternoon Tea - BioIndustry Exhibition Hall |
| 5:00pm – 5:30pm | Coaches to the Venue depart Melbourne Convention Centre, Porte Cochere Main Entrance, Convention Centre Place, opposite Hilton South Wharf Hotel |
| 6:00pm – 7:30pm | AUSBIOTECH 2010 WELCOME RECEPTION <i>For registered delegates only</i> <i>Venue To Be Advised</i> Sponsored by Victorian Government |
| From 7:00pm | Coaches depart Venue to return delegates to the Melbourne Convention Centre |

WEDNESDAY 20 OCTOBER

| | | | | |
|--|--|---|--|--|
| 7:30am – 8:30am | SATELLITE EVENT Davies Collison Cave Breakfast Meeting Room 212, Melbourne Convention Centre Separate registration required, further information at www.ausbiotech2010.com.au | | | |
| 9:00am – 11:00am <i>Auditorium, Level 2, Melbourne Exhibition Centre</i> | OPENING OF AUSBIOTECH 2010 – Opened by TBA <i>Auditorium, Level 2, Melbourne Exhibition Centre</i> AWARD PRESENTATIONS - AusBiotech 2010 Excellence Awards – Sponsored by Roche - AusBiotech–GSK Student Awards – Sponsored by GlaxoSmithKline PLENARY 1 - Mr James C. Greenwood, President and CEO, Biotechnology Industry Organization, Washington D.C., United States PLENARY 2 - Dr David Nicholson, Senior Vice President and Head Worldwide Licensing and Knowledge Management, Merck Worldwide Laboratories, New Jersey, United States Dr Bonnie Bain, Global Research and Analysis Director, Datamonitor Healthcare, United States | | | |
| 11:00am – 11:30am | Morning Tea - BioIndustry Exhibition Hall | | | |
| 11:30am – 1:00pm <i>Concurrent Sessions: Level 2, Melbourne Exhibition Centre</i> | 1. MEDTECH Level 2, MEC Cell therapy commercialisation: Look think and act from a different point of view To highlight the challenges being faced in the exciting and rapidly emerging Cell Therapy market, how companies around the world are addressing these issues and the vital role that Australian companies are currently playing. Chair: Dr David Haylock, Associate Professor Research Scientist, Materials Science and | 2. HUMAN HEALTH Level 2, MEC Regulation in Key Markets Chair: (TBC) Speakers: Michele Yelmene, United States Dr Dianne Jackson-Matthews, Deputy Group Director, Regulatory Affairs, ERA Consulting (Australia) Pty Ltd Dr Chaline Brown, Senior Director Clinical | 3. AG / INDUSTRIAL / FOOD Level 2, MEC Biofuels - Algae as a Factory Chair: Professor Paul Greenfield AO, Vice-Chancellor and President, University of Queensland (TBC) Speakers: Professor Ben Hankamer, Institute for Molecular Bioscience, The University of Queensland | 4. INVESTMENT / BUSINESS Level 2, MEC International Financing – new options and opportunities This session will outline several new innovative finance options now available to Australian companies and introduce key international investors who have invested and are interested in investing in Australian life science companies Chair: Jeremy Curnock – Cook, Managing Director, IB Australia |

| | | | | |
|--|--|--|--|--|
| | <p>Engineering, CSIRO (TBC)</p> <p>Speakers: David James, Director Manufacturing Innovation, Invetech Pty Ltd</p> <p>Dr Geoff Symonds, Chief Scientific Officer, Calimmune Australia</p> <p>Dr Kilian Kelly, Director, Regulatory and Clinical, Mesoblast</p> <p>Sunil Mehta, Director Technology Development, KBI Biopharma Inc., North Carolina, United States</p> | <p>Affairs, Ground Zero Pharmaceuticals Ltd, California, United States</p> | | <p>Bioscience Fund Pty Ltd</p> <p>Speakers: Dr Selena Chaisson, Director of Healthcare Developments, Bailard, United States</p> <p>Malcolm Thompson, La Jolle Cove Investors, United States</p> <p>Phillip Valliere, Senior Vice President, SpringTree Global Investors, LLC, New York, United States</p> <p>Todd C. Davis, Cowen Healthcare Royalty Partners, United States</p> |
|--|--|--|--|--|

1:00pm – 2:00pm Lunch - BioIndustry Exhibition Hall

| | | | | |
|--|---|---|--|---|
| <p>2:00pm – 3:30pm</p> <p>Concurrent Sessions: <i>Level 2, Melbourne Exhibition Centre</i></p> | <p>5. MEDTECH Level 2, MEC</p> <p>New Technologies for Point of Care</p> <p>Recent advances in key enabling technologies such as nanotechnology, biotechnology and information technology promises tremendous opportunity and potential cost reductions for diagnostic applications in a range of different market sectors, including food, agricultural, environmental, pharmaceutical and medical. Medical diagnostics is of particular importance where the demand for low cost, highly accurate and widely available diagnostic tests is ever increasing, especially for the realisation of systems for Point of Care applications.</p> <p>The development of new Point of Care diagnostic products based on these new enabling technologies is very often a complex and demanding task. Solutions rely on a combination of factors: development of enabling technologies for the modular components; integration of key components into systems using novel, low cost manufacturing techniques; interfacing of systems to the external environment and most importantly, understanding the requirements of the user community and target markets. To achieve this successfully (both technically and commercially) is a significant challenge and requires the combination of multi skills and disciplines, often residing in multiple partners and companies.</p> | <p>6. HUMAN HEALTH Level 2, MEC</p> <p>Maximising Australia’s Investment in Medical Research – new approaches to discovery and commercialisation</p> <p>Australia through its strengths in the areas of medical research and innovation has demonstrated an ability to create local solutions that meet global challenges be it in the area of immunisation, oncology through to anti-virals. Continuing to be a global player will require new ways of co-operating plus continuing support for the biotechnology sector from the Government. Research Australia, as the representative body for the Health research sector will outline its proposed new policy framework for encouraging greater co-operation within the research sector and by the research sector with industry.</p> <p>The subject will be discussed and debated by a panel of leading research participants from industry, government, academia and the research community. Research Australia will also discuss its recent polling on what the Australian population thinks of medical research, and how public support for research can be harnessed to contribute to industry growth</p> <p>Chair: Alex Gosman, Alex Gosman Consulting</p> <p>Speakers: Rebecca James, Chief Executive Officer,</p> | <p>7. GENERAL Level 2, MEC</p> <p>Solutions that protect and improve performance (session title TBC)</p> <p>Session chair and speakers to be confirmed</p> | <p>8. INVESTMENT / BUSINESS Level 2, MEC</p> <p>Venture Capital and Life Sciences in Australia Today. How does this compare with the Global Situation?</p> <p>This session will discuss the situation in Australia in regard to Venture Capital and Biotech. The panel will comprise the representatives of the main Venture Capital firms in Australia.</p> <p>Chair and speaker: Dr Mike Hirschorn, Four Hats Capital</p> <p>Speakers: Dr Andrew Baker, GBS Venture Partners</p> <p>Dr David Fisher, Founding Partner, Brandon Capital Partners</p> <p>Dr Carrie Hillyard, Co-Founder, CM Capital</p> <p>Fiona Pak Poy, General Partner, Innovation Capital</p> |
|--|---|---|--|---|

*Conference Program as at 2 August 2010 - subject to change

| | | | | |
|-----------------|---|---|--|--|
| | <p>Chair: (TBC)</p> <p>Speakers: Andrew Lysikatos, Chief Executive Officer, Axxin</p> <p>Dr Andrew Campitelli, Programme Director, Biotechnology, MiniFAB</p> <p>Associate Professor David Anderson, Deputy Director, Head, Business Development Office, NHMRC Senior Research Fellow, Burnet Institute (TBC)</p> | <p>Research Australia</p> <p>Nick Gruen, Chief Executive Officer, Lateral Economics</p> <p>Professor Warwick Anderson, Chief Executive Officer, NHMRC</p> <p>Dr Ashley Bates, Head of Drug Development, GlaxoSmithKline</p> | | |
| 3:30pm – 4:00pm | <p>Afternoon Tea - BioIndustry Exhibition Hall</p> <p><i>Sponsored by Government of Canada / Province of Manitoba</i></p> | | | |
| 4:00pm – 5:30pm | <p>9. GENERAL Level 2, MEC</p> <p>International Collaboration in Nanotechnology <i>(session title TBC)</i></p> <p><i>Session chair and speakers to be confirmed</i></p> | <p>10. HUMAN HEALTH Level 2, MEC</p> <p>Translating Hope into Help</p> <p>Translating Cancer Research into practical applications for patients</p> <p>Chair: Mr Ian Thompson, General Manager, Amgen Inc. (TBC)</p> <p>Professor Sean Grimmond, Director, Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland</p> <p>Professor Andrew Biankin, Head, Pancreatic Cancer Research, Cancer Program, Garvan Institute of Medical Research</p> <p>Associate Professor David Thomas, Medical Director, Oncologist, Peter MacCallum Cancer Centre (TBC)</p> | <p>11. AG / INDUSTRIAL / FOOD Level 2, MEC</p> <p>Future-proofing Australia: Products for a sustainable bioeconomy</p> <p>This session will explore the opportunity and hurdles of building a biobased economy based on Australian technologies and resources. Speakers will address the production of chemicals, for the pharmaceutical and industrial chemicals sectors. The production of industrial polymers from renewable feedstocks will be examined. Lastly, the role of specialised biofuels, in this case, aviation jet fuels will be considered.</p> <p>Chair: Dr Dianne Glenn, Principal, Corelli Consulting</p> <p>Speakers: Dr Ann Roberts, Project Manager, Plantic Technologies Ltd</p> <p>Dr Jens Kroemer, Australian Institute for Bioengineering & Nanotechnology (AIBN) The University of Queensland</p> <p>Dr Bill Lyons, VP and GM, Boeing Research & Technology Australia</p> | <p>12. INVESTMENT / BUSINESS Level 2, MEC</p> <p>Innovative Business Development Models</p> <p>This session will concentrate on public sector.</p> <p>Chair and speaker: Dr Charlie Day, Chief Executive Officer, Melbourne Ventures</p> <p>Speakers: Dr Julian Clark, Head of Business Development, Walter and Eliza Hall Institute</p> <p>Dr Dean Moss, General Manager Life Sciences, UniQuest</p> <p>Josh Hexter, Director, Early Development Program, BioLineRx Ltd, Israel</p> |
| 5:30pm – 7:00pm | <p>INTERNATIONAL RECEPTION <i>BioIndustry Exhibition Hall</i></p> | | | |
| 7:00pm – 8:00pm | <p>AusBiotech 2010 Major Partners VIP Reception <i>By invitation only</i></p> | | | |

THURSDAY 21 OCTOBER

| | | | | |
|---|--|--|--|---|
| 7:30am – 8:30am | PricewaterhouseCoopers Breakfast Meeting Room 212, Melbourne Convention Centre Separate registration required, further information at www.ausbiotech2010.com.au | | | |
| 9:00am – 11:00am <i>Auditorium, Level 2, Melbourne Exhibition Centre</i> | PLENARY 3 - Millis Oration – Sponsored by CSL Limited Introduction: Dr Andrew Cuthbertson, Director of Research and Development and Chief Scientific Officer, CSL Limited <i>Speaker to be confirmed</i> PLENARY 4 - <i>Speaker to be confirmed</i> | | | |
| 11:00am – 11:30am | Morning Tea - BioIndustry Exhibition Hall <i>Sponsored by CSL Limited</i> | | | |
| 11:30am – 1:00pm Concurrent Sessions: <i>Level 2, Melbourne Exhibition Centre</i> | <p style="text-align: center;">13. MEDTECH Level 2, MEC</p> <p style="text-align: center;">Biomarkers</p> <p>There is a pretty rapid change in regulatory landscape in this space – where both US and European regulators have put in place separate arrangements to qualify biomarkers independent of diagnostic kits which have a lot of implications for diagnostics (and therapeutics) developers.</p> <p>This would allow presentation of the whole pathway – from identification and qualification of the biomarker through to the final “kit in a box”. Getting this right can make market access very much smoother for developers.</p> <p><i>Session chair and speakers to be confirmed</i></p> | <p style="text-align: center;">14. HUMAN HEALTH Level 2, MEC</p> <p style="text-align: center;">Big Pharma Scouts – what they want and what you get</p> <p>This session will outline what big pharma are looking for and how to interface with their local scouts.</p> <p>Chair: Glenn Cross, Chief Operating Officer, AusBiotech Ltd</p> <p>Speakers: Dr Phil Kearney, Director, Licensing & External Research, Merck Sharp & Dohme Dr Ashley Bates, Head of Drug Development, GlaxoSmithKline Dr Daniel Grant, Director, Asia R&D Business Development, Pfizer Australia Paul Juniewicz, VP Global Access to External Innovation, Sanofi-Aventis, United States (TBC)</p> | <p style="text-align: center;">15. GENERAL Level 2, MEC</p> <p style="text-align: center;">Tax R & D / Gene Patenting (session title TBC)</p> <p><i>Session chair and speakers to be confirmed</i></p> | <p style="text-align: center;">16. INVESTMENT / BUSINESS Level 2, MEC</p> <p style="text-align: center;">Future global trends in the life sciences industry – industry & legal trends</p> <p>The aim of the session is to assist the biotech industry to gain insights into global trends in this area and provide them with the depth of our knowledge in Australia and the United States. The audience will receive a snapshot of the market trends across the life sciences sector in the United States as well as key legal implications to consider when operating in an Australian and global market.</p> <p>Chair: Tony Conaghan, Lead Partner, Intellectual Property & Technology Practice, DLA Phillips Fox – Australia</p> <p>Speakers: Dr Lisa Haile, Partner Life Sciences Practice, DLA Piper - United States Bruce Jenett, Partner Life Sciences Practice, DLA Piper - United States Melanie Kelly, Director, Life Sciences and Health Care practice, Deloitte Economics Dr Gabby Fennessy, Manager, Policy and Strategy, Research Australia</p> |

| | | | | |
|---|---|--|---|---|
| | | | | Sponsored by DLA Phillips Fox |
| 1:00pm – 2:00pm | Lunch – BioIndustry Exhibition Hall | | | |
| | Sponsored by the Victorian Government | | | |
| 2:00pm – 3:30pm Concurrent Sessions: <i>Level 2, Melbourne Exhibition Centre</i> | <p>17. MEDTECH Level 2, MEC</p> <p>Developing Award Winning Medical Devices (session title TBC)</p> <p>Chair: Dr Greg Roger, Advanced Design Surgical Manufacture (TBC)</p> <p>Speakers: Tim Peacocke, Business Director, Design + Industry</p> <p>Lusia Guthrie, Chief Executive Officer & Managing Director, LBT Innovations Ltd</p> <p>David Mulcahy, Vice President Product Development, Global Sleep SBU, ResMed Ltd</p> | <p>18. HUMAN HEALTH Level 2, MEC</p> <p>Understanding the implications of the rapidly evolving US healthcare and regulatory environment</p> <p>The regulatory and commercialisation pathway for both biologics and small molecules is changing almost daily as the full implications of the 2,700 page healthcare reform package are unveiled and as the Obama administration introduces other initiatives designed to 'bend the cost curve'. It's now a brave new world in the US and Australian biotechs need to understand the new requirements, complications and hurdles imposed by the new regulatory environment in the world's most important pharma market.</p> <p>Chair and speaker: Peter Molloy, Aquarius Consulting, United States</p> <p>Jayson Slotnik, Counsel, Foley Hoag LLP, Washington DC, United States</p> <p>Other US speaker to be confirmed</p> | <p>19. AG / INDUSTRIAL / FOOD Level 2, MEC</p> <p>Evidence based complementary medicines for human and animal use: International Trends and Opportunities in Integrative Health</p> <p>Consumers are demanding it, government policy and regulatory changes are afoot and the multinational pharmaceutical industry is investing heavily in integrative approaches to prevention and cure. Growing international demand for high quality complementary medicines, with a sound scientific base of evidence, is attracting considerable investment.</p> <p>This session will discuss international trends, the fast changing regulatory environment in Australia and Canada and models for strategic co-development partnerships required to build a successful global complementary medicines business. Acknowledging the growing importance of complementary medicines, how can the broader Life Sciences community contribute to its effective integration with traditional biotechnological and pharmaceutical approaches to health.</p> <p><i>Session speakers will include globally focussed Canadian companies investing heavily in R&D and international collaborations.</i></p> | <p>20. INVESTMENT / BUSINESS Level 2, MEC</p> <p>How does the Australian public market react to news?</p> <p>The Life-science Australian public market is both only small in scale and receives limited analyst and media coverage. Consequently announcements and news may be interpreted and communicated to the public via a small number of sources. This session explores the public's ability to analyse newsflow and the affect of analyst/media coverage. Format will include a case study from an ASX listed company, examining its shareprice movements vs. news flow.</p> <p>Chair: Ben Gust, Investment Manager, GBS Venture Partners</p> <p>Speakers: David Blake, BioShares</p> <p>Dr Karen Bernstein, Chairman and Editor in Chief, BioCentury, United States (TBC)</p> <p>Dr Greg Collier, Chief Executive Officer and Managing Director, ChemGenex Pharmaceuticals</p> |
| invited | <p>AUSBIOTECH 2010 TRADE AFTERNOON BioIndustry Exhibition Hall</p> <p>The AusBiotech BioIndustry Exhibition is the largest biotechnology exhibition assembled in Australia. The exhibition showcases the latest in business and product services, equipment, instrumentation, devices and state-of-the-art technology. The Trade Afternoon is offered in addition to general access of the BioIndustry Exhibition for exhibitors and delegates. This time has been allocated specifically for exhibitors to invite guests and for graduate and undergraduate students to attend and engage with industry.</p> | | | |
| 3:30pm – 4:00pm | Afternoon Tea - BioIndustry Exhibition Hall | | | |
| 4:00pm – 5:30pm Concurrent Sessions: <i>Level 2, Melbourne Exhibition Centre</i> | <p>21. GENERAL Level 2, MEC</p> <p>Credible and incredible!</p> | <p>22. HUMAN HEALTH Level 2, MEC</p> <p>Research Ethics & Governance</p> | <p>23. AG / INDUSTRIAL / FOOD Level 2, MEC</p> <p>Plant biotechnology in Support of the</p> | <p>24. INVESTMENT / BUSINESS Level 2, MEC</p> <p>Deal or No Deal?:</p> |

| | | | | |
|------------------|---|---|--|--|
| | <p>How to communicate with investors, regulators and prescribers</p> <p>At this session, nationally and internationally recognised experts will identify what you should and shouldn't do when communicating with investors, regulators, and prescribers. Our experts will highlight specific communication tactics for each audience and what incredible means to each of them. They will also reinforce the strategic and commercial importance of providing all audiences with credible material. Unethical communication practices from Australians have already been featured in the New York Times and Wall Street Journal – investors, regulators, and prescribers don't need to read about another "blunder from down under"! Attend this session to make sure you don't make the next one.</p> <p>Chair: Dr Christine Wichems, Medical Communications Manager, CSL Limited</p> <p>Speakers: Andy Jane, Partner, CM Capital</p> <p>Dr Jamie McGinness, Director, Clinical Evaluation Section 4, Office of Prescription Medicines, Therapeutic Goods Administration</p> <p>Associate Professor Karen Woolley, CEO, ProScribe Medical Communications</p> | <p>– State initiatives for global trials</p> <p>Initiatives towards enabling timely commencement of clinical trials in Australia have been undertaken by state jurisdictions with the aim of harmonising processes for ethics and governance approvals, which contributes to making Australia a location of choice for trials.</p> <p>This session will include an overview from the Victorian Department of Health, NSW Health and Queensland Health on their state-based approaches to single ethical review. Joint initiatives across these three states will be described, including standard indemnity, trial agreements and guidance, use of the same IT platform and coordinated development of site authorisation processes.</p> <p>Chair: Bill Karanatsios, Client Relationship Manager, Public Healthcare and Medical Research, Victorian Managed Insurance Authority</p> <p>Speakers: Dr Suzanne Hasthorpe, Manager, Coordinating Office for Human Research Ethics, Victoria</p> <p>Sue Jenkins-Marsh, Principal Project Officer, Office of Health & Medical Research, Queensland Health</p> <p>Dr Jo Mitchell, Associate Director Research, Ethics and Public Health Training, NSW Health</p> <p>Mitch Kirkman, Manager- Process, Training and Quality, International Clinical Operations and Oncology General Monitoring Organisation, Novartis</p> | <p>Millennium Development Goals</p> <p>Chair: Dr Murray McLaughlin, President & CEO, Sustainable Chemistry Alliance, Toronto, Canada (TBC)</p> <p>Speakers: Professor Emeritus Ingo Potrykus, Chairman Humanitarian Golden Rice Board & Network, Switzerland</p> <p>Dr TJ Higgins, Deputy Chief, CSIRO Division of Plant Industry</p> <p>Professor German Spangenberg, Executive Director, Biosciences Research Division, Department of Primary Industries & Professor, Plant Genetics and Genomics La Trobe University</p> | <p>Option Based Partnering Deals</p> <p>Biotech-Pharma partnering is recovering its high level of partnering activity post GFC. Big pharma continues to manage risk and opportunity with the externalisation of their R&D engines. Deal structures are increasingly risk modified, in licensors' and acquirers' favour. In particular, option based deal structure are becoming a norm, with the full engagement of the partner dependent on a significant, short-term milestone. This session examines recent deals following this trend and discusses views from a range of stakeholders on both sides of these deals – investors, big pharma & biotech deal makers, analysts.</p> <p>Chair: Robin Coleman, PharmBio Deals</p> <p>Speakers: Dr Leigh Farrell, VP Business Development, Biota Holdings Ltd</p> <p>Dr Richard Treagus, CEO, Acrux Ltd</p> <p>Dr Josh Funder, Partner, GBS Venture Partners</p> <p>Dr Graeme Wald, Analyst, Wilson HTM</p> <p>Dr Rob Armstrong, Vice President, Global External Research and Development, Eli Lilly and Company, United States (TBC)</p> |
| 7:00pm – 11:30pm | <p>AUSBIOTECH 2010 CONFERENCE DINNER <i>Melbourne Convention and Exhibition Centre – Rooms 201 & 202, Level 2.</i></p> <p><i>Sponsored by Pfizer</i></p> | | | |

FRIDAY 22 OCTOBER

| | |
|--|---|
| 9:00am – 9:30am <i>Auditorium, Level 2, Melbourne Exhibition Centre</i> | <p>PLENARY 5 – <i>Speaker to be confirmed</i></p> |
|--|---|

| | | | |
|---|---|---|--|
| <p>9:30am – 11:00am</p> <p>Concurrent Sessions: <i>Level 2, Melbourne Exhibition Centre</i></p> | <p style="text-align: center;">25. GENERAL Level 2, MEC</p> <p style="text-align: center;">Building reputation to drive corporate strategy: A masterclass in biotech communications</p> <p>This interactive masterclass in biotechnology communications will bust the myth that scientists, businesses and investors make decisions based solely on data. Veteran communicators from pharma and biotech will provide examples and demonstrate how perceptions create reputations and brands. They will explore ways that companies, large and small, have successfully built and managed their reputation and in some cases used it to support and drive their strategy. Best and worst practise will be shown, providing valuable tips on how best to build trust and confidence, as well as using emotion to engage and persuade stakeholders.</p> <p>Chair and speaker: Sue Charles, Managing Partner, College Hill Life Sciences, London, United Kingdom</p> <p>Speakers: Margaret Stuart, Margaret Stuart and Associates, Public Relations and Strategic Communications</p> <p>Peter Sandbach, Head of Communications, Roche Partnering, F. Hoffmann-La Roche AG, Switzerland</p> <p>Nick Woolf, Executive Director, Phylogica</p> | <p style="text-align: center;">26. AG / INDUSTRIAL / FOOD Level 2, MEC</p> <p style="text-align: center;">Food legal / IP / food standards (session title TBC)</p> <p>Chair: Professor Linda Tapsell, Professor, School of Health Sciences, Faculty of Health and Behavioural Sciences & Director, Smart Foods Centre, University of Wollongong</p> <p>Speakers: Joe Lederman, Managing Principal, FoodLegal</p> <p>Dr Andrew Kelly, Executive Director, BioPacificVentures, New Zealand</p> <p>Bruce Dowsing or Amanada Jones, Watermark</p> | <p style="text-align: center;">27. INVESTMENT / BUSINESS Level 2, MEC</p> <p style="text-align: center;">Think Locally, Act Globally: Successfully taking Australian intellectual capital to the world stage</p> <p>This session will provide three speakers and a moderated panel discussion of the strategies, both theoretical and practical, for commercialising the inventions of Australian companies successfully on to the world stage.</p> <p>It will provide the perspective of at least two successful Australian companies, at least one which has "gone it alone" in taking their technology to the world, and the other of which has, alternately, commercialised their technology through partners. The session will not assume that patent protection is necessary and will provide a roadmap for successful commercialisation from a company that has not relied on patent protection for its products. The speakers will address:</p> <ul style="list-style-type: none"> • finding the right business model for technology exploitation, • how to find the right partner, • what to do when partnerships don't go as planned, • getting through the funding drought in early stage technology development <p>Chair: Karen Sinclair, Principal, Watermark Patent & Trade Marks Attorneys, and President, Licensing Executives Society of Australia and New Zealand, Inc.</p> <p>Speakers: Dr Simon Tucker, Vice President, President, Research Biota Holdings Limited (TBC)</p> <p>Associate Professor David Darby, CogState Limited (TBC)</p> <p>Mel Bridges, Managing Director, Parma Corporation Pty Ltd</p> |
| <p>11:00am – 11:30am Morning Tea - BioIndustry Exhibition Hall</p> | | | |
| <p>11:30am – 1:00pm</p> <p>Concurrent Sessions: <i>Level 2, Melbourne Exhibition Centre</i></p> | <p style="text-align: center;">28. MEDTECH Level 2, MEC</p> <p style="text-align: center;">Wireless Medical Devices (session title TBC)</p> <p style="text-align: center;"><i>Session chair and speakers to be confirmed</i></p> | <p style="text-align: center;">29. HUMAN HEALTH Level 2, MEC</p> <p style="text-align: center;">India – beyond contract manufacturing</p> <p>With rising costs and low productivity in successful new drug launches globally, Asian CROs (in particular Indian and Chinese) are already playing a significant role in driving innovation. While India has emerged as a major global player (second only to the US) in the FDA approved contract manufacturing base since the 80s and 90s, it is quickly emerging as a mature destination to outsource for high quality, low cost early stage R&D and preclinical work. In</p> | <p style="text-align: center;">30. INVESTMENT / BUSINESS Level 2, MEC</p> <p style="text-align: center;">Creating Global Value in Product Development: from Proof of Principle to Regulatory Strategy</p> <p>This session is designed to enlighten attendees on ways in which product development can be streamlined to enable global acceptability of data and thus accelerate product development. From discussions of the early preclinical phase of the product life cycle, to formal nonclinical and clinical development and then to regulatory filings, this session will provide tips on ways to maximize product</p> |

| | | | |
|-----------------|---|---|---|
| | | <p>addition, access to modern, high quality hospital infrastructure operated by well-trained clinicians as well as availability of a large population of drug-naïve patients in all major disease areas, has enabled India to carve a growing share of global multi-centric clinical trials market. This session gives an overview of what the Indian CRAMs industry has looked like in the past, its development today and it's vision for the future as well as opportunities for funding.</p> <p>Chair and speaker: Mr Swapan Bhattacharya, CEO, TCG Life Sciences, India</p> <p>Speakers: Dr Julia Hill, Director, Mantrax Ventures</p> <p>Dr Arun Bhatt, President, Clininvent Pvt Ltd, India</p> <p>Hareesh Parandhaman, Head of Business Development, Lupin, India</p> <p>Australian company to be confirmed</p> | <p>development results, with the added benefit of controlling costs for the overall program. Within the individual topics, advice on best practices and approaches will be provided, along with points for consideration as products move from research and development through to clinical phases. The concluding presentations, from two different points of view, will comment and focus on bringing together these points to illustrate the value in approaching product development with the objective of satisfying international expectations for new biotechnological and drug products. Lastly, the Speakers hope to generate good discussion during a Question and Answer period at the end of the session.</p> <p>Chair: Dr Gabriel Kremmidiotis, Vice President Discovery Research, Biomomics Limited</p> <p>Speakers: Dr Valentia Lee-Brotherton, Director, Toxicology, Ashuren Health Sciences, Canada</p> <p>Dr Ken Draper, Senior Director, Scientific Operations, LAB Research Inc., Canada</p> <p>Nicholas Peace, Investment Director, Starfish Ventures Pty Ltd</p> <p>Dr Michael Thurn, Chief Executive Officer, Mimetica Pty Ltd. - discussion ongoing with an individual involved in clinical planning at an Australian biotech company</p> <p>Dr Pete Smith, Chief Executive Officer, Alchemia Limited (TBC)</p> |
| 1:00pm – 2:30pm | <p>AUSBIOTECH 2010 CLOSING RECEPTION and WELCOME TO AUSBIOTECH 2011 <i>BioIndustry Exhibition Hall</i></p> | | |
| 2:30pm – 3:30pm | <p>AusBiotech Ltd Annual General Meeting <i>Room TBA</i> All AusBiotech members are encouraged to attend and participate at the Annual General Meeting</p> | | |